Your Mitochondrial Stack Might Be Missing the FMN and FAD Synthesis Layer

Short answer: Your cells build two flavin cofactors from riboflavin — FMN, which sits at the electron-entry site of Complex I, and FAD, the coenzyme used by Complex II, glutathione reductase, the acyl-CoA dehydrogenases, and MTHFR. That conversion takes three inputs, not one: riboflavin as substrate, ATP as the phosphate donor, and Mg²⁺ as the metal cofactor FAD synthase (EC 2.7.7.2) requires. Most riboflavin products supply the substrate alone. BioActive Vitamin B2™ supplies all three in one daily capsule: 100 mg riboflavin as riboflavin-5′-phosphate sodium, 50 mg magnesium as bisglycinate chelate, and 250 mg D-ribose. No human trial has tested this combination against heart-rate variability, fat oxidation, or redox outcomes, and this article says so at every point where the evidence stops. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

In this guide: the riboflavin → FMN → FAD pathway step by step · what FAD synthase needs and why magnesium matters · what each of the three ingredients does · which biomarkers you can track · safety and upper limits · full dose disclosure and evidence · stack fit · FAQs · verified references.

Your stack is thorough. NAD+ handled with a nicotinamide-riboside precursor. Electron transport addressed with CoQ10. HRV logged every night, homocysteine on the quarterly panel, CGM running on fasted morning sessions. You’ve covered the layers you can see, and you’re tracking the outputs.

One input most stacks don’t address as a system is the riboflavin → FMN → FAD synthesis pathway. This article is about that pathway’s biochemistry, how the formula maps onto it, and where the human evidence stops. It isn’t a promise about any number you track.

That gap isn’t a knock on your protocol. It’s one the whole category tends to skip. NAD+ precursors and CoQ10 work right alongside the flavin-dependent complexes of the electron transport chain: Complex I runs on FMN, Complex II runs on FAD. These are the flavin cofactors your cells build from riboflavin, and their supply depends on how completely that synthesis pathway is supported.

BioActive Vitamin B2™ is formulated around the three documented inputs to flavin cofactor synthesis, rather than riboflavin alone: substrate (R5P, riboflavin’s phosphorylated form), the enzymatic cofactor (Mg²⁺, the metal FAD synthase requires for adenylyl transfer), and ATP-substrate support (D-ribose, backing the enzyme’s ATP requirement rather than doing standalone ATP recovery, a distinction we break down in the Deep Dive below).

If you track HRV with an Oura, a Whoop, or an Apple Watch, the FMN/FAD synthesis pathway is one input that standard B vitamin products don’t address as a system. Here’s the biochemistry, stated carefully. FMN and FAD are the flavin cofactors for Complex I (NADH:ubiquinone oxidoreductase, which uses FMN at its electron-entry site) and Complex II (succinate:ubiquinone oxidoreductase, which carries a covalently bound FAD). That much is established.

What isn’t established is any downstream performance outcome in people. No human trial has tested riboflavin, R5P, magnesium bisglycinate, or D-ribose against heart-rate-variability or fat-oxidation outcomes at all. Redox status has been tested in a randomized trial at 50 and 100 mg/day riboflavin — the higher of those is exactly this product’s dose — and no change in systemic redox status was found (Bourgonje et al., 2022). So we make no claim that this product changes any of them. What we’ve done is build the formula around the pathway’s documented inputs and give you the biomarkers to watch for yourself. Individual results vary.

BioActive Vitamin B2™ is informed by the enzymology of human FAD synthase, which requires Mg²⁺ and is specific for ATP as its phosphate donor (BRENDA, EC 2.7.7.2, Homo sapiens), and by McNulty et al. (2006, Circulation), a genotype-stratified riboflavin trial discussed accurately below.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What Is the Tri-Cofactor Activation System™, and What Does It Contain?

Systems-level design around three documented inputs: R5P substrate, the Mg²⁺ that FAD synthase requires, and ATP-substrate support.

BioActive Vitamin B2™ is developed by Triquetra Health for people ages 25 to 45 who track HRV, continuous glucose monitoring, and bloodwork panels as part of a systematic self-optimization protocol. Each 1-capsule serving provides 100 mg riboflavin (as riboflavin-5′-phosphate sodium, 7,692% of the Daily Value), 50 mg magnesium (as magnesium bisglycinate chelate, 12% of the Daily Value), and 250 mg D-ribose, with 60 servings per 60-capsule bottle — a two-month supply at one capsule daily with food. Other ingredients: vegetarian capsule (HPMC), rice fiber, and diatomaceous earth. For transparency: each serving supplies 137 mg of riboflavin-5′-phosphate sodium. The USP–NF monograph for riboflavin 5′-phosphate sodium specifies a riboflavin content of 73.0% to 79.0% by weight on the dried basis, so 137 mg of compendial-grade material delivers at least 100 mg of riboflavin — which is the figure the Supplement Facts panel declares. These amounts sit inside the Tri-Cofactor Activation System™ — a formulation name describing the three synthesis inputs the formula includes, not a claim about any physiological outcome — built around each input to flavin cofactor synthesis: substrate (R5P, riboflavin’s phosphorylated form), enzymatic cofactor (Mg²⁺, required by FAD synthase), and ATP-substrate support (D-ribose, scoped to the enzyme’s ATP requirement, not standalone ATP recovery).

Every batch is tested by an independent third-party laboratory for potency (meeting or exceeding label claim), heavy metals, and microbiological safety, consistent with the third-party batch-testing standard published on the product page. Heavy-metal results are within the permitted daily exposure limits of USP General Chapter ⟨2232⟩ (lead: 5 µg/day). It’s manufactured in a facility operating under current Good Manufacturing Practice requirements for dietary supplements (21 CFR Part 111). Certificates of Analysis are available on request.

Biomarker Tracking Protocol (set baselines before you start):

 

Why Isn’t Flavin Cofactor Synthesis Documented on Most Supplement Labels?

You treat your biology the way an engineer treats a system. Nothing in your stack got there by accident. Every component has a documented mechanism, a target pathway, and a biomarker to check it against. NAD+ for Complex I electron entry and sirtuin activation. CoQ10 for mobile electron transport between complexes. Methylfolate and methylcobalamin for the methylation stack. Sleep protocol, stress management, cold exposure, all dialed in and tracked.

So when a layer is missing from the design, it’s usually not because you skipped it. It’s because the category never documented it well enough for you to evaluate. That’s the situation with flavin cofactor synthesis: the enzymology is settled and sitting in the primary literature, and almost none of it makes it onto a label or a product page.

The analytical part of you finds most supplement copy maddening. Every brand claims to “support mitochondrial function.” Almost none hand you the pathway documentation, the enzyme nomenclature, or the primary-literature citations you’d need to check the mechanism yourself, and fewer still tell you plainly where the human evidence stops. We’ve tried to do both here: give you the biochemistry, and be explicit about which downstream outcomes have not been tested in people. Several of them haven’t, and we say so in the sections below rather than leaving you to assume otherwise.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Do NAD+ Precursors, CoQ10, or Isolated R5P Already Cover the Flavin Layer?

Every piece of your stack does something real. Each one also works on a layer distinct from flavin cofactor synthesis.

Take NAD+ precursors on their own. They address the NAD+/NADH ratio that matters for Complex I electron entry, and they activate sirtuin-dependent mitochondrial biogenesis. That’s a different biochemical layer from flavin cofactor supply. Complex I uses FMN and Complex II uses FAD as their flavin cofactors for electron transfer, and flavin supply is governed by the synthesis pathway, not by NAD+ concentration. So flavin-synthesis support is a parallel input, complementary to a NAD+ protocol rather than a duplicate of it.

CoQ10 and PQQ are next. They give you mobile electron transport between Complexes I, II, and III, plus biogenesis signaling through CREB and NRF2. Their function depends on electrons reaching ubiquinone from the flavin-dependent complexes upstream. Complex II uses FAD to oxidize succinate and pass electrons to CoQ10. So the flavin layer and the mobile-carrier layer are addressing different steps of the same chain.

Isolated R5P is a well-characterized, GRAS-affirmed form of riboflavin (21 CFR § 184.1697), and we use it here. We won’t claim it outperforms plain riboflavin, though: most orally administered R5P is dephosphorylated before absorption (see the absorption note below), and we haven’t found a human study showing an advantage over riboflavin itself. What R5P alone doesn’t include is the Mg²⁺ that FAD synthase requires to convert FMN into FAD. That cofactor, supplied alongside the substrate rather than assumed to be abundant, is the formulation logic here.

Each of these targets a real part of mitochondrial function. Flavin cofactor synthesis is simply a different node, and it’s the one this formula is built around.

How Does the Body Convert Riboflavin Into FMN and FAD?

The design logic in one line: R5P substrate, the Mg²⁺ cofactor FAD synthase requires, and ATP-substrate support, addressed together rather than substrate alone.

FMN and FAD Synthesis: The Riboflavin → FMN → FAD Pathway, Step by Step

 

(Note: Complex I uses FMN; FAD is used by Complex II and the enzymes above)

How FAD Synthase (EC 2.7.7.2) Works, and Why Magnesium Matters

FAD synthase (the FMN-adenylyltransferase activity) runs the final step of cellular FAD biosynthesis: it transfers an adenylyl group from ATP onto FMN, producing FAD and pyrophosphate. The human enzyme requires Mg²⁺ and is highly specific for ATP as its phosphate donor (BRENDA, EC 2.7.7.2, Homo sapiens). That Mg²⁺ requirement rests on enzymology, not on a solved metal-bound structure: the full-length human enzyme’s architecture was reported by Leo et al. (2024, Structure), and the bacterial and yeast structures often cited for this enzyme (Herguedas et al., 2010; Leulliot et al., 2010) place it in the PP-loop nucleotidyltransferase superfamily but do not themselves contain a bound magnesium ion. Practically, if FAD synthase is short on Mg²⁺, the final FMN → FAD conversion is under-supported no matter how much FMN is present, and FAD is the coenzyme Complex II, glutathione reductase, the acyl-CoA dehydrogenases, and MTHFR actually use. Our formula supplies chelated magnesium bisglycinate alongside R5P and D-ribose for exactly this step.

What Does Each Ingredient Do, and at Which Step?

Component 1: Riboflavin as Riboflavin-5′-Phosphate Sodium — 100 mg riboflavin per serving

Delivers riboflavin in its phosphorylated form. Any R5P that reaches a cell intact is already FMN and wouldn’t need the riboflavin kinase (EC 2.7.1.26) step — but most orally administered R5P is dephosphorylated in the intestine and absorbed as free riboflavin (Jusko & Levy, 1967; Zempleni et al., 1996), so we don’t claim that step is bypassed in practice. We use R5P because it’s the form specified in 21 CFR § 184.1697 and is well characterized, not on a claim of superior delivery. Riboflavin-5′-phosphate sodium is roughly 73% riboflavin by weight — a property of the salt itself, not a purity grade, and the reason the USP–NF monograph specifies a riboflavin content of 73.0% to 79.0% on the dried basis. The panel therefore declares the riboflavin the salt delivers, 100 mg, rather than the 137 mg weight of the salt. That is 7,692% of the 1.3 mg Daily Value for adults and children age 4 and older.

A high percentage of the Daily Value is a dosing fact, not a benefit in itself, and it is worth stating plainly that riboflavin absorption saturates. The body absorbs little riboflavin from single doses beyond about 27 mg, and excess amounts are either not absorbed or excreted in urine (NIH Office of Dietary Supplements; Zempleni et al., 1996). So a substantial fraction of a 100 mg serving is not absorbed. We include the dose at this level for a saturating margin above the roughly 27 mg single-dose ceiling, not on any claim that all 100 mg is absorbed or that more absorbed riboflavin produces a larger effect. The salt used meets the USP–NF monograph for riboflavin 5′-phosphate sodium (identity and assay); we describe it as compendial- or USP-grade rather than “pharmaceutical-grade,” a term with no regulatory definition for dietary supplements.

Component 2: Magnesium as Magnesium Bisglycinate Chelate — 50 mg elemental magnesium per serving (12% of the Daily Value)

Supplies the Mg²⁺ that FAD synthase requires. Magnesium bisglycinate is a chelated form in which magnesium is bound to two glycine molecules. In a double-blind randomized crossover isotope study in patients with ileal resection, magnesium diglycinate and magnesium oxide showed similar overall absorption (23.5% vs. 22.8%), but the diglycinate was better tolerated by all patients, reached peak absorption earlier, and the authors concluded some portion is absorbed intact, probably via a dipeptide route (Schuette et al., 1994).

Human absorption data comparing magnesium forms is mixed: a 2024 double-blind randomized crossover trial found no significant plasma-magnesium rise from magnesium bisglycinate, while citrate and a microencapsulated form did rise (Pajuelo et al., 2024, industry-funded). We use bisglycinate for tolerability at a low, catalytic dose, not on a claim of superior absorption. At 50 mg, this is 12% of the Daily Value — a cofactor-targeting amount, not a full magnesium serving. Because this is a low cofactor-targeting dose, people who want higher magnesium for sleep or neuromuscular function should supplement that separately, and should count this product’s magnesium toward the 350 mg/day tolerable upper intake level for supplemental magnesium (NIH Office of Dietary Supplements).

On stress and magnesium: magnesium is lost in sweat and urine, so requirements can run higher with heavy training. Whether that translates into a limitation on FAD synthesis specifically has not been tested in humans, so we treat it as a rationale for adequacy, not as a demonstrated effect.

Component 3: D-Ribose — 250 mg per serving

ATP-substrate support for the energy-dependent FAD synthase reaction. D-ribose enters nucleotide-synthesis pathways via the pentose phosphate pathway, which is the rationale for including it alongside the FMN substrate and the Mg²⁺ cofactor. Whether ATP availability actually limits FAD synthase in healthy adults has not been tested, so this is formulation rationale rather than a demonstrated effect.

Critical dose transparency: 250 mg sits far below the multi-gram doses used in standalone ATP-recovery research, and that’s intentional. Seifert et al. (2017, JISSN) tested 10 g/day D-ribose against dextrose in a double-blind crossover (n=26), with benefits confined to the lower-fitness subgroup and no difference in the higher-fitness group. Other D-ribose research has used multi-gram daily doses in the same range. For safety context rather than dosing, EFSA set an acceptable level of intake of 36 mg/kg body weight per day, about 2,500 mg for a 70 kg adult, derived from animal toxicology with a 100-fold uncertainty factor (EFSA NDA Panel, 2018b). Our 250 mg is about a tenth of that ceiling, and if you take a separate high-dose D-ribose product you should count both toward that total. 

Our 250 mg does one narrower job: it supports ATP availability for FAD synthase. It is not a dose for standalone ATP recovery, and we make no ATP-recovery claim; for that goal, a separate high-dose D-ribose product is the right tool. Note: the principal D-ribose exercise literature includes work by authors with a commercial interest in ribose ingredients, which is worth knowing when you read it.

What do FMN and FAD do in energy metabolism? They’re the flavin cofactors of two electron transport chain complexes. Complex I (NADH:ubiquinone oxidoreductase) carries FMN at its electron-entry site and moves electrons through iron-sulfur clusters to ubiquinone. Complex II (succinate:ubiquinone oxidoreductase) carries FAD and oxidizes succinate to fumarate while handing electrons to ubiquinone. Both depend on flavin availability, which depends on the synthesis pathway: riboflavin → FMN (via riboflavin kinase) → FAD (via FAD synthase, which needs Mg²⁺ and ATP). That’s established biochemistry (Powers, 2003, a narrative review). We are describing the pathway the formula supports, not asserting a clinical outcome.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Which Biomarkers Can You Track Alongside Flavin-Synthesis Support?

The formula is built around the flavin cofactor pathway. Here’s how to think about the numbers you already track, with the evidence stated honestly.

Does Riboflavin or Magnesium Change HRV?

Flavin cofactors FMN and FAD are required by Complex I and Complex II of the electron transport chain. That’s biochemistry. But no human trial has tested riboflavin, R5P, magnesium bisglycinate, or D-ribose against heart-rate-variability outcomes, so we make no claim that this product changes HRV. A 2020 review of human studies on micronutrients and HRV concluded that the evidence remains limited and inconsistent, with the clearest signals for vitamin D and B-12 status rather than for riboflavin or magnesium supplementation (Lopresti, 2020). Many people in quantified-self protocols already log HRV; if you do, it’s one of several data points you can track alongside any change to your regimen. Individual results vary.

How Are Riboflavin, MTHFR, and Homocysteine Connected?

MTHFR (methylenetetrahydrofolate reductase) uses FAD as its cofactor to convert 5,10-methyleneTHF to 5-methylTHF, which supports remethylation of homocysteine to methionine. Here’s what the most-cited trial actually found, stated exactly: in a genotype-stratified randomized trial, 1.6 mg/day riboflavin for 12 weeks lowered homocysteine by as much as 22% (from about 16.1 to 12.5 µmol/L), and by roughly 40% in those with the lowest baseline riboflavin status, only in adults with the MTHFR 677TT genotype whose homocysteine was elevated at baseline. No response occurred in the CC or CT genotypes (McNulty et al., 2006). Two things follow that we want to be straight about: the study dose of 1.6 mg/day is roughly 60 times below this product’s 100 mg, and no trial has tested 100 mg for homocysteine at all. Beyond that, no trial has tested riboflavin’s effect on homocysteine that’s already within the normal range, or in non-TT genotypes. So this is context for a methylation biomarker you may choose to track, not a claim about your result.*

Tracking protocol: baseline homocysteine before starting, retest no earlier than 12 weeks. Response, if any, tends to vary with MTHFR genotype and starting level.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Does Riboflavin Change Fat Oxidation or Metabolic Flexibility?

Acyl-CoA dehydrogenases (LCAD, MCAD, SCAD) that carry out fatty-acid beta-oxidation use FAD as their cofactor. That’s established biochemistry. Evidence that riboflavin supplementation changes fat oxidation comes from animal studies (da Silva-Araújo et al., 2025, a systematic review restricted to preclinical studies); no human trial has measured fat oxidation, CGM glucose patterns, or metabolic flexibility with any ingredient in this formula, and we make no claim that it does. If you track CGM during fasted training, treat it as neutral self-monitoring.*

What Is EGRac, and What Does It Actually Measure?

Glutathione reductase is a FAD-dependent enzyme that regenerates reduced glutathione from its oxidized form. That’s established biochemistry (Ashoori & Saedisomeolia, 2014, a narrative review drawing largely on animal and reperfusion data). In humans, though, a randomized, double-blind, placebo-controlled trial of 50 mg and 100 mg/day riboflavin in healthy volunteers found no change in systemic redox status (Bourgonje et al., 2022, the RIBOGUT trial). One of the two doses tested, 100 mg/day, is exactly this product’s riboflavin dose. So this is not an extrapolation from a lower dose or an inference from a higher one: the best available human evidence tested this dose directly, in healthy volunteers, and found no change in systemic redox status. We therefore make no antioxidant claim for this product, and we would rather tell you that than leave the impression the question is open. EGRac remains a validated marker of riboflavin status itself.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Is 100 mg of Riboflavin Safe? What to Expect and Who Should Check First

At 100 mg riboflavin, bright yellow urine is expected and harmless; it reflects the portion your body does not absorb being excreted. The Food and Nutrition Board did not establish a tolerable upper intake level for riboflavin, because adverse effects from high riboflavin intakes from foods or supplements — specifically 400 mg/day for at least 3 months — have not been reported. This product’s 100 mg per serving is a quarter of that intake. The same source adds that limited adverse-effect data do not mean high intakes have no adverse effects, and urges caution about consuming excessive amounts (NIH Office of Dietary Supplements). The tolerable upper intake level for supplemental magnesium is 350 mg/day for adults, and this product’s 50 mg sits well under it (NIH Office of Dietary Supplements); still, count this product’s magnesium toward that total if you also take a separate magnesium supplement.

On D-ribose and blood glucose: EFSA’s panel reviewed human studies indicating a potential decrease in glucose levels and the occurrence of transient symptomatic hypoglycaemia at intakes of 10 g of D-ribose, and from those studies defined 70 mg/kg body weight per day — about 4,900 mg for a 70 kg adult — as the no-observed-adverse-effect level with respect to hypoglycaemia in adults (EFSA NDA Panel, 2018a). This product contains 250 mg per serving, roughly 40 times below the 10 g intake at which those effects were seen and about a twentieth of that hypoglycaemia NOAEL, and no glucose-lowering effect has been reported at this dose.

Separately, the UK authorisation for D-ribose requires foods containing it to carry a statement that they should not be used if D-ribose food supplements are consumed the same day (Food Standards Agency), so if you take a separate D-ribose product, don’t stack them on the same day. If you manage blood glucose clinically, or you are pregnant, nursing, or taking any prescription medication, talk to your healthcare provider before starting.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What Does the Evidence Actually Show? Full Dose Disclosure

Structural biochemistry. The human enzyme’s architecture was reported by Leo et al. (2024, Structure), which describes the crystal structure of full-length human FAD synthase (hFADS2) and its FAD-bound C-terminal domain. Bacterial and yeast structures (Herguedas et al., 2010, PDB 2X0K; Leulliot et al., 2010, PDB 2WSI) place the enzyme in the PP-loop nucleotidyltransferase superfamily; neither deposited structure contains a bound magnesium ion, so the Mg²⁺ requirement rests on enzymology (BRENDA, EC 2.7.7.2) rather than on those structures. For the upstream step, Karthikeyan et al. (2003, Structure, PDB 1NB0) solved human riboflavin kinase with an intrinsically bound Mg-ADP.

The MTHFR–riboflavin literature. McNulty et al. (2006) is restated accurately above: 1.6 mg/day, 12 weeks, response confined to the 677TT genotype with elevated baseline homocysteine. Two further trials from the same group, Wilson et al. (2013) and Ward et al. (2020, the JINGO project), studied riboflavin and blood pressure in hypertensive or general Irish populations. Those are blood-pressure studies in specific clinical or observational populations; we list them for background only and make no blood-pressure or hypertension claim for this product. (Note: several authors of that body of work hold a patent on riboflavin for hypertension.)

On the C677T variant and flavin. In a structural study of E. coli MTHFR, the mutation equivalent to the human C677T variant did not change Km or kcat but increased the enzyme’s tendency to lose its FAD cofactor; folate derivatives protected against that loss (Guenther et al., 1999). This is bacterial-enzyme structural work, not a human trial, and it does not establish that supplemental riboflavin stabilizes human MTHFR.

Magnesium form. See Component 2 above: Schuette et al. (1994) for tolerability and the dipeptide-route inference, and Pajuelo et al. (2024) as contrary human evidence on absorption. We do not claim bisglycinate is better absorbed than oxide.

D-ribose dose context. Seifert et al. (2017), 10 g/day, benefit confined to the lower-fitness subgroup. EFSA’s acceptable level of intake is about 2,500 mg for a 70 kg adult, a safety ceiling derived from animal toxicology rather than a studied dose. Our 250 mg is a fraction of both and is scoped to FAD synthase’s ATP requirement, not ATP recovery.

R5P absorption, disclosed plainly. Orally administered R5P is largely dephosphorylated in the intestine before absorption, with free riboflavin as the primary absorbed form (Jusko & Levy, 1967; Zempleni et al., 1996, which tested 20, 40, and 60 mg oral doses and found maximum single-dose absorption of about 27 mg). So we make no bypass or superior-delivery claim for R5P. We have not found a human study demonstrating an advantage of R5P over riboflavin, and we’d rather say that plainly than imply one.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Where Does BioActive Vitamin B2™ Fit in a Mitochondrial Optimization Stack?

FOR HRV-TRACKING BIOHACKERS:

✓ BioActive Vitamin B2™ addresses the flavin cofactor synthesis pathway at all three documented inputs. No human trial has tested any ingredient in this formula against HRV; HRV is a self-tracked data point here, not a promised outcome. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

○ Riboflavin taken on its own, at any dose, does not address the Mg²⁺ requirement of FAD synthase.

✗ Multi-ingredient energy complexes with undisclosed B2 doses give you no way to assess form, dose, or cofactor inclusion.

FOR PERFORMANCE ATHLETES INTERESTED IN METABOLIC FLEXIBILITY:

✓ BioActive Vitamin B2™ supplies riboflavin, the precursor your cells use to build the FAD cofactor that fatty-acid beta-oxidation enzymes depend on, plus the Mg²⁺ that final step requires. It does not contain FAD itself. No human fat-oxidation outcome is claimed. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

○ MCT oil or exogenous ketones provide fat-derived substrate directly, a different mechanism.

✗ Stimulant-based pre-workouts give acute alertness without touching cofactor supply.

FOR HOMOCYSTEINE/METHYLATION TRACKERS:

✓ BioActive Vitamin B2™ supplies riboflavin, the precursor of the FAD cofactor MTHFR uses. The riboflavin–MTHFR homocysteine effect is documented only in the 677TT genotype with elevated baseline homocysteine, at 1.6 mg/day (McNulty et al., 2006); see the accurate restatement above. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

○ Methylfolate + methylcobalamin address substrates downstream of MTHFR.

✗ Betaine (TMG) alone supports the alternative BHMT pathway, not the FAD-dependent MTHFR step.

FOR SYSTEMS-LEVEL STACKS (NAD+/CoQ10 CONTEXT):

✓ BioActive Vitamin B2™ supplies the riboflavin precursor and the Mg²⁺ cofactor for the flavin synthesis pathway that produces Complex I’s FMN and Complex II’s FAD — an input NAD+ precursors and CoQ10 don’t provide. Complementary, not duplicative. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

○ Alpha-lipoic acid is studied mainly as a redox-active compound; lipoic acid’s role in pyruvate dehydrogenase is as an enzyme-bound cofactor, a distinct mechanism from flavin cofactor supply.

✗ Generic B-complex products bring arbitrary ratios and inactive forms, and some exceed the 100 mg/day tolerable upper intake level for vitamin B6. That upper limit is precautionary: the Food and Nutrition Board set it by halving the roughly 200 mg/day dose at which long-term studies found no neuropathy, while the severe sensory neuropathy reported in the literature followed chronic intakes in the 1–6 gram per day range (NIH Office of Dietary Supplements).

FOR QUANTIFIED BIOMARKER TRACKERS:

✓ BioActive Vitamin B2™ gives you a defined, transparent formula plus biomarkers to watch: EGRac for riboflavin status, and homocysteine as a methylation marker. HRV, CGM, and redox are neutral self-tracking, not claimed outcomes. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

○ Any supplement with transparent dosing and a third-party COA meets the baseline standard.

✗ Brands without a COA or cGMP documentation fail a basic data-integrity test.

The Mitochondrial Stack Integration Map

 

 

Frequently Asked Questions

How does this fit with my existing NAD+/CoQ10 stack?

It’s complementary, because it supplies a different input. NAD+ precursors support the NAD+/NADH ratio for Complex I electron entry and sirtuin activation. CoQ10 is the mobile electron carrier between Complexes I, II, and III. BioActive Vitamin B2™ supplies riboflavin plus the Mg²⁺ cofactor for the pathway your cells use to build Complex I’s FMN and Complex II’s FAD; it does not contain FMN or FAD themselves. These are different steps of the same chain, so it’s meant to sit alongside your existing stack, not replace any of it. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

My EGRac tested normal. Do I still need this?

EGRac reflects average riboflavin status. It’s a status marker, not a measure of downstream performance, and it doesn’t tell you whether FAD synthase has abundant Mg²⁺. If your EGRac is adequate and you have no plateau you’re trying to address, you may not need it. We’re not going to tell you a normal marker is secretly abnormal. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

What are the biomarkers and timelines?

Four you can track. HRV: 2-week baseline, then daily at a consistent time, as neutral self-monitoring. Homocysteine: baseline, retest no earlier than 12 weeks, as a methylation marker. CGM during fasted training: neutral self-monitoring. EGRac: a validated riboflavin-status marker. We make no claim about what these will show; track consistently and talk with your healthcare provider about interpretation. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

Why 250 mg of D-ribose rather than a multi-gram dose?

Because its job here is narrow: supporting ATP availability for the FAD synthase reaction (FMN + ATP + Mg²⁺ → FAD + PPi), not ATP-pool restoration. Standalone ATP-recovery research uses multi-gram doses (Seifert et al., 2017, 10 g/day), and EFSA’s acceptable level of intake — a safety ceiling, not a target — works out to about 2,500 mg for a 70 kg adult. Our 250 mg is a fraction of both figures. For an ATP-recovery goal, a separate high-dose product is the right tool. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

What about drug interactions?

The interactions we can document: magnesium-containing supplements can reduce the absorption of oral bisphosphonates such as alendronate, so separate them by at least 2 hours in either direction. Magnesium can also form insoluble complexes with tetracycline antibiotics (for example doxycycline) and quinolone antibiotics (for example ciprofloxacin, levofloxacin); those antibiotics should be taken at least 2 hours before, or 4 to 6 hours after, a magnesium-containing supplement (NIH Office of Dietary Supplements). Riboflavin is not known to have clinically relevant medication interactions (NIH ODS). If you take any prescription medication, talk to your healthcare provider before starting or changing any supplement. These statements have not been evaluated by the Food and Drug Administration; this product is not intended to diagnose, treat, cure, or prevent any disease.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The Bottom Line

BioActive Vitamin B2™ is formulated around the three documented inputs to flavin cofactor synthesis: R5P substrate, the Mg²⁺ that FAD synthase requires, and ATP-substrate support. The biochemistry is in the primary literature and cited below. Where human outcome evidence exists, we’ve stated it exactly; where it doesn’t exist, for HRV and fat oxidation, we’ve said so; and where the best available human trial tested this product’s exact riboflavin dose of 100 mg/day and came back null, for systemic redox status, we’ve said that too. That’s the standard we think a formula for this audience should meet.

Learn More About BioActive Vitamin B2™ →

Third-party tested. Manufactured under 21 CFR Part 111 cGMP requirements. Backed by Triquetra’s 30-day 100% money-back guarantee on supplements purchased directly from TriquetraHealth.com — full refund or exchange within 30 days of the purchase date, upon return of the opened or unopened item (refund policy).

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Scientific References & Citations

Every reference below was verified against PubMed, DOI resolution, the Protein Data Bank, or the issuing agency. Verified August 27, 2026.

Peer-Reviewed Clinical and Mechanistic Studies

Ashoori, M., & Saedisomeolia, A. (2014). Riboflavin (vitamin B₂) and oxidative stress: A review. British Journal of Nutrition, 111(11), 1985–1991. https://doi.org/10.1017/S0007114514000178 (PMID 24650639) — narrative review.

Bourgonje, A. R., Otten, A. T., Sadaghian Sadabad, M., von Martels, J. Z. H., Bulthuis, M. L. C., Faber, K. N., van Goor, H., Dijkstra, G., & Harmsen, H. J. M. (2022). The effect of riboflavin supplementation on the systemic redox status in healthy volunteers: A post-hoc analysis of the RIBOGUT trial. Free Radical Biology and Medicine, 190, 169–178. https://doi.org/10.1016/j.freeradbiomed.2022.08.008 (PMID 35973668) — RCT, n=99, 50 and 100 mg/day; no change in systemic redox status.

da Silva-Araújo, E. R., Toscano, A. E., Silva, P. B. P., Pereira dos Santos Junior, J., Gouveia, H. J. C. B., da Silva, M. M., Souza, V. da S., de Freitas Silva, S. R., & Manhães-de-Castro, R. (2025). Effects of deficiency or supplementation of riboflavin on energy metabolism: A systematic review with preclinical studies. Nutrition Reviews, 83(2), e332–e342. https://doi.org/10.1093/nutrit/nuae041 (PMID 38719205) — preclinical studies only.

Guenther, B. D., Sheppard, C. A., Tran, P., Rozen, R., Matthews, R. G., & Ludwig, M. L. (1999). The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nature Structural Biology, 6(4), 359–365. https://doi.org/10.1038/7594 (PMID 10201405) — bacterial enzyme; folate protected against flavin loss.

Herguedas, B., Martínez-Júlvez, M., Frago, S., Medina, M., & Hermoso, J. A. (2010). Oligomeric state in the crystal structure of modular FAD synthetase provides insights into its sequential catalysis in prokaryotes. Journal of Molecular Biology, 400(2), 218–230. https://doi.org/10.1016/j.jmb.2010.05.018 (PMID 20471397; PDB 2X0K — no bound Mg²⁺).

Jusko, W. J., & Levy, G. (1967). Absorption, metabolism, and excretion of riboflavin-5′-phosphate in man. Journal of Pharmaceutical Sciences, 56(1), 58–62. https://doi.org/10.1002/jps.2600560112 (PMID 6030496).

Karthikeyan, S., Zhou, Q., Mseeh, F., Grishin, N. V., Osterman, A. L., & Zhang, H. (2003). Crystal structure of human riboflavin kinase reveals a beta barrel fold and a novel active site arch. Structure, 11(3), 265–273. https://doi.org/10.1016/S0969-2126(03)00024-8 (PMID 12623014; PDB 1NB0 contains bound ADP and Mg²⁺).

Leo, G., Leone, P., Ataie Kachoie, E., Tolomeo, M., Galluccio, M., Indiveri, C., Barile, M., & Capaldi, S. (2024). Structural insights into the bifunctional enzyme human FAD synthase. Structure, 32(7), 953–965.e5. https://doi.org/10.1016/j.str.2024.04.006 (PMID 38688286).

Leulliot, N., Blondeau, K., Keller, J., Ulryck, N., Quevillon-Cheruel, S., & van Tilbeurgh, H. (2010). Crystal structure of yeast FAD synthetase (Fad1) in complex with FAD. Journal of Molecular Biology, 398(5), 641–646. https://doi.org/10.1016/j.jmb.2010.03.040 (PMID 20359485; PDB 2WSI).

Lienhart, W.-D., Gudipati, V., & Macheroux, P. (2013). The human flavoproteome. Archives of Biochemistry and Biophysics, 535(2), 150–162. https://doi.org/10.1016/j.abb.2013.02.015 (PMID 23500531) — ~90 human flavoproteins.

Lopresti, A. L. (2020). Association between micronutrients and heart rate variability: A review of human studies. Advances in Nutrition, 11(3), 559–575. https://doi.org/10.1093/advances/nmz136 (PMID 31942924) — evidence limited and inconsistent; clearest signals for vitamin D and B-12 status.

McNulty, H., Dowey, R. C., Strain, J. J., Dunne, A., Ward, M., Molloy, A. M., McAnena, L. B., Hughes, J. P., Hannon-Fletcher, M., & Scott, J. M. (2006). Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation, 113(1), 74–80. https://doi.org/10.1161/CIRCULATIONAHA.105.580332 (PMID 16380544) — 1.6 mg/day for 12 weeks; response confined to 677TT.

Pajuelo, D., Meissner, J. M., Negra, T., Connolly, A., & Mullor, J. L. (2024). Comparative clinical study on magnesium absorption and side effects after oral intake of microencapsulated magnesium versus other magnesium sources. Nutrients, 16(24), 4367. https://doi.org/10.3390/nu16244367 (PMID 39770988) — double-blind crossover, n=40; no significant plasma-magnesium rise from bisglycinate; industry-funded.

Powers, H. J. (2003). Riboflavin (vitamin B-2) and health. American Journal of Clinical Nutrition, 77(6), 1352–1360. https://doi.org/10.1093/ajcn/77.6.1352 (PMID 12791609) — narrative review.

Schuette, S. A., Lashner, B. A., & Janghorbani, M. (1994). Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. Journal of Parenteral and Enteral Nutrition, 18(5), 430–435. https://doi.org/10.1177/0148607194018005430 (PMID 7815675) — overall absorption similar to oxide; diglycinate better tolerated.

Seifert, J. G., Brumet, A., & St Cyr, J. A. (2017). The influence of D-ribose ingestion and fitness level on performance and recovery. Journal of the International Society of Sports Nutrition, 14, Article 47. https://doi.org/10.1186/s12970-017-0205-8 (PMID 29296106) — 10 g/day; effect confined to the lower-fitness subgroup; an author holds a commercial interest in ribose ingredients.

Ward, M., Hughes, C. F., Strain, J. J., Reilly, R., Cunningham, C., Molloy, A. M., Horigan, G., Casey, M., McCarroll, K., O’Kane, M., Gibney, M. J., Flynn, A., Walton, J., McNulty, B. A., McCann, A., Kirwan, L., Scott, J. M., & McNulty, H. (2020). Impact of the common MTHFR 677C→T polymorphism on blood pressure in adulthood and role of riboflavin in modifying the genetic risk of hypertension: Evidence from the JINGO project. BMC Medicine, 18(1), 318. https://doi.org/10.1186/s12916-020-01780-x (PMID 33172445) — observational; background only.

Wilson, C. P., McNulty, H., Ward, M., Strain, J. J., Trouton, T. G., Hoeft, B. A., Weber, P., Roos, F. F., Horigan, G., McAnena, L., & Scott, J. M. (2013). Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: Findings of a targeted randomized trial. Hypertension, 61(6), 1302–1308. https://doi.org/10.1161/HYPERTENSIONAHA.111.01047 (PMID 23608654) — background only; not a basis for any claim here.

Zempleni, J., Galloway, J. R., & McCormick, D. B. (1996). Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. American Journal of Clinical Nutrition, 63(1), 54–66. https://doi.org/10.1093/ajcn/63.1.54 (PMID 8604671) — maximum single-dose absorption ~27 mg.

Reference Standards and Enzyme Data

BRENDA Enzyme Database. EC 2.7.7.2 — FAD synthase (Homo sapiens). Technische Universität Braunschweig. https://www.brenda-enzymes.org/enzyme.php?ecno=2.7.7.2

National Institutes of Health, Office of Dietary Supplements. Riboflavin: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/

National Institutes of Health, Office of Dietary Supplements. Magnesium: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/

National Institutes of Health, Office of Dietary Supplements. Vitamin B6: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/

RCSB Protein Data Bank. 1NB0: Crystal structure of human riboflavin kinase (ligands: ADP, Mg²⁺). https://www.rcsb.org/structure/1NB0

RCSB Protein Data Bank. 2WSI: Yeast FAD synthetase (Fad1) in complex with FAD (ligand: FAD; no bound Mg²⁺). https://www.rcsb.org/structure/2WSI

RCSB Protein Data Bank. 2X0K: Modular FAD synthetase (ligands: pyrophosphate, sulfate; no bound Mg²⁺). https://www.rcsb.org/structure/2X0K

Regulatory and Safety Documentation

European Food Safety Authority, NDA Panel. (2018a). Safety of d-ribose as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 16(5), e05265. https://doi.org/10.2903/j.efsa.2018.5265 (PMID 32625902) — potential decrease in glucose levels and transient symptomatic hypoglycaemia reported at intakes of 10 g; hypoglycaemia NOAEL of 70 mg/kg body weight per day defined for adults.

European Food Safety Authority, NDA Panel. (2018b). Statement on the safety of d-ribose. EFSA Journal, 16(12), e05485. https://doi.org/10.2903/j.efsa.2018.5485 (PMID 32625778) — acceptable level of intake 36 mg/kg body weight per day, derived from a rat NOAEL of 3.6 g/kg bw/day with a 100-fold uncertainty factor; notes that concurrent use of d-ribose supplements may exceed that level.

Food Standards Agency. Regulated products register — novel food authorisation: d-ribose (novel-39). https://data.food.gov.uk/regulated-products/novel_authorisations/novel-39 — authorised in England, Scotland, and Wales; labelling of foods containing d-ribose must state that they should not be used if d-ribose food supplements are consumed the same day.

U.S. Food and Drug Administration. GRAS Notice Inventory — d-ribose, GRN 100 and GRN 243 (notifier Bioenergy, Inc.). GRN 243’s intended use is conditioned on co-use with an additional carbohydrate energy source. https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory

U.S. Food and Drug Administration. 21 CFR § 101.93 — Certain types of statements for dietary supplements (the required disclaimer and the 30-day notification requirement for structure/function claims). https://www.ecfr.gov/current/title-21/section-101.93

U.S. Food and Drug Administration. 21 CFR § 184.1697 — Riboflavin-5′-phosphate (sodium). https://www.ecfr.gov/current/title-21/section-184.1697

U.S. Food and Drug Administration. 21 CFR Part 111 — Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111

U.S. Food and Drug Administration. 21 CFR Part 184 — Direct Food Substances Affirmed as Generally Recognized as Safe. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-184 — magnesium bisglycinate is a lawfully marketed dietary ingredient used as a mineral source, but it is not the subject of a Part 184 GRAS affirmation. Part 184 affirms magnesium carbonate, chloride, hydroxide, oxide, phosphate, stearate, and sulfate, not glycinate.

United States Pharmacopeia. Riboflavin 5′-Phosphate Sodium (USP–NF monograph M73550) — compendial specification of 73.0% to 79.0% riboflavin content on the dried basis, the basis for 137 mg of the salt supplying at least 100 mg of riboflavin. https://doi.usp.org/USPNF/USPNF_M73550_01_01.html

United States Pharmacopeia. USP–NF General Chapter ⟨2232⟩ Elemental Contaminants in Dietary Supplements — permitted daily exposure: lead 5 µg/day, inorganic arsenic 15 µg/day, cadmium 5 µg/day, total mercury 15 µg/day. USP–NF general chapters are published under subscription and have no free public URL. https://www.usp.org/

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.